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network of interrelated pathways is disturbed, causing the 
interruption of the control of B-cell proliferation and pro-
grammed cell death.
Keywords BLV · Cattle · Host response · Gene 
expression · Microarrays
Introduction
Enzootic bovine leukosis (EBL) is the most prevalent, 
lethal neoplastic disease of cattle, causing considerable 
economic losses worldwide. The etiological agent of EBL 
is a B-lymphocytotropic deltaretrovirus, named BLV 
(Bovine Leukemia Virus), which infects cattle and has dis-
tinct clinical outcomes. Most cattle infected by BLV remain 
clinically silent in an aluekemic state, approximately 30% 
of infected animals develop a persistent lymphocytosis 
(PL) which is a benign polyclonal proliferation of B cells, 
and finally, lethal lymphoma or lymphosarcoma appears in 
less than 5% of infected animals, after a long latency period 
[40]. After infection, BLV distributes in the host as inte-
grated proviral DNA, spreading via the cell divisions of 
the infected leukocytes [20]. The course of leukemogen-
esis caused by BLV, likewise the mechanisms underlying 
the aspect of host resistance/susceptibility to BLV infec-
tion and disease progression, are intricate and obscured. 
Although it is not entirely clear, it seems likely that the sub-
tle balance between viral gene expression and efficient host 
immune response plays a decisive role in the outcome of 
BLV infection. Furthermore, tumor development in EBL is 
preceded by an accumulation of chromosomal aberrations 
and mutations in oncogenes e.g. the p53 gene [8, 18].
An apparent puzzle of BLV-induced leukemogenesis 
is the fact that in  vivo BLV is quiescent in the majority 
Abstract The aim of the present study was to examine 
gene expression changes in response to bovine leukemia 
virus (BLV) infection, in an effort to determine genes that 
take a part in molecular events leading to persistent lym-
phocytosis (PL), and to better define genes involved in host 
response to BLV infection. Using bovine 70-mer oligonu-
cleotide spotted microarrays (BLOPlus) and qRT-PCR vali-
dation, we studied global gene expression profiles in blood 
cells in vivo of 12 naturally BLV-infected Polish Holstein 
cows, and 12 BLV non-infected controls of the same breed 
and reared in herds with high BLV seroprevalence. With an 
arbitrary cut-off value of 1.5-fold change in gene expres-
sion, we identified the down-regulation of 212 genes (M 
value ≤−0.585) and the up-regulation of 158 genes (M 
value of ≥0.585) at 1% false discovery rate in BLV-posi-
tive animals in comparison to the BLV-negative group. The 
gene set enrichment analysis demonstrated that the differ-
entially expressed (DE) genes could be classified to diverse 
biological processes, including immune response of host 
blood cells. Interestingly, our data indicated the potential 
involvement of the innate immunity, including complement 
system activation, NK-cell cytotoxicity and TREM-1 sign-
aling, during the BLV-induced pathogenesis. We showed 
the occurrence of numerous regulatory processes that are 
targeted by BLV-infection. We also suggest that a complex 
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of infected cells, however, vigorous humoral immune 
response has been elicited in BLV-infected cattle, indicat-
ing that BLV is not completely silent. Furthermore, the 
latent state is immediately reversed when infected lympho-
cytes are subjected to transient ex  vivo cell culture. The 
potential repression mechanism of viral expression involves 
a poorly defined plasma blocking factor (PBF), related to 
fibronectin and inhibited by a platelet lysate [11, 13, 50].
A number of reports suggest that the multifunctional 
viral accessory protein Tax is the major transforming pro-
tein of BLV (reviewed in [13]). The ability of this viral 
transactivator to both transcriptionally regulate cellular 
gene expression and directly interact with cellular pro-
teins provides the basis for leukemogenesis [22]. Microar-
ray transcription profiling of ovine immortalized Clone2 
B-cell line and peripheral blood-derived ovine B cells cul-
tured in  vitro [22] and human HeLa cells [4] transfected 
with TaxBLV constructs revealed that in  vitro Tax was an 
efficient modulator of host gene transcription. A vast list 
of Tax-responsive genes contained, among others, genes 
encoding for cytokines, immune modulators, transcription 
factors, genes associated with cell cycle, DNA repair and 
apoptosis, signaling factors and adhesion molecules which 
could be involved in BLV-induced pathogenesis. It is not 
yet known whether similar changes in host gene expression 
occur in vivo during EBL progression in naturally infected 
cattle.
Evidence to date suggests that host genetic factors may 
play a role at different stages of infection with BLV: from 
initial infection to the likelihood of developing PL, through 
to the fatal lymphoma [14]. It was proved that the resist-
ance and susceptibility to PL development was linked 
with the MHC class II BoLA-DRB3 gene [26]. The resist-
ance occurs to be dependent upon the presence of polar 
motif ER at positions 70–71 within a highly polymorphic 
region encoding the putative peptide binding domain [52]. 
Recently, one of the alleles containing the ER motif, des-
ignated as BoLA–DRB3.2*0902, was shown to be signifi-
cantly associated with genetic resistance to PL and with a 
low proviral load profile (LPL) [20]. It was proposed that 
animals presenting LPL profile and harboring the BoLA–
DRB3.2*0902 allele might be unable to transmit BLV in 
herd conditions, and this suggestion underlay a marker-
assisted selection scheme for the simultaneous eradica-
tion of BLV and improvement of milk production traits 
implemented in Argentina [11]. However, the extent of 
variation in LPL profile not associated with the favora-
ble BoLA–DRB3.2*0902 allele [11] implies that genetic 
resistance to BLV and the outcome of the disease could be 
under the control of multiple as yet unknown or unidenti-
fied genes, each contributing slightly to the phenotype. In 
addition, polymorphism in the predicted enhancer region 
of the bovine TNF-α (tumor necrosis factor, allele −824G 
associated with low transcription activity) was shown to 
contribute in the progression of BLV-induced lymphoma 
[23].
As variation in gene expression could be a causative 
mechanism underlying BLV resistance/susceptibility, the 
application of gene expression microarray technology 
enabling the large scale transcriptome profiling of host 
immune response promises the identification of networks 
of genes involved in disease pathogenesis, providing a key 
for understanding and, perhaps in the future, intervening 
against successful BLV evasion of host biodefenses. The 
aim of the present study was to examine gene expression 
changes in response to BLV infection, in an effort to deter-
mine genes that take a part in molecular events leading to 
PL, and to better define genes involved in host response 
to BLV infection. We focused on fresh whole blood cells, 
with their transcriptome freezed and captured immediately 
after bleeding using RNA stabilization solution, without 
culturing them because most of these cells in vivo usually 
do not express viral proteins including Tax, in contrast to 
either cultured PBMCs from BLV-positive animals or BLV-
infected cell lines.
Materials and methods
Animals, sample collection and BLV diagnostics
All procedures were approved by the local ethics commit-
tee of University of Warmia and Mazury in Olsztyn (no. 
13/2008/N/T). Blood samples were collected from two 
dairy herds, kept in a free stall barn system and located in 
north-eastern and north-western parts of Poland respec-
tively. BLV seroprevalence rates in both herds exceeded 
70%. All sampled animals belonged to the Polish Hol-
stein–Friesian breed and were reared and maintained in the 
infected herd at least 3 years. The blood was taken from 
jugular vein of lactating cows using Vacuette® Blood Col-
lection Set and evacuated blood collection tubes: Vacu-
ette® Serum, Vacuette® EDTA (Greiner Bio-One) and 
Vacuette® Tempus™ Blood RNA Tube (Applied Biosys-
tems, Greiner Bio-One). In other to minimize seasonal 
effects, all the samples were collected within a single 
month (November, 2012). BLV serological diagnostics 
was carried out by ELISA technique using Pourquier® 
ELISA Bovine Leukosis Screening Kit (Institute Pourquier) 
according to the manufacture’s protocol. Moreover, the 
diagnosis was validated with a molecular approach based 
on BLV proviral DNA detection using nested-PCR method 
[29]. Automated blood cell counting was performed with 
SF3000 automated hematology analyzer (Sysmex) accord-
ing to the manufacture’s instructions. Based on serological 
(ELISA), molecular (nested-PCR proviral detection) and 
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hematological assays, the experimental group was com-
posed of 12 BLV-infected individuals with apparent hema-
tological alterations characteristic for the lymphoprolifera-
tive stage of enzootic bovine leukosis (average lymphocyte 
count × 103/μl, 15.16 ± 10.28) and the control group was 
composed of 12 BLV free animals with normal hemato-
logical blood indices (average lymphocyte count × 103/μl, 
3.43 ± 1.22). The difference in average age of the animals 
in the experimental group (5 years 2 months, SD = 0.81) 
and of the control group (4 years 8 months, SD = 0.58) was 
not significant.
RNA extraction
Blood samples of 3 ml volume were collected into Vacu-
ette® Tempus™ Blood RNA Tube (Applied Biosystems, 
Greiner Bio-One) containing 6 ml RNA stabilization solu-
tion, mixed vigorously, transported on ice within a few 
hours to the laboratory and then frozen in −20 °C until 
RNA isolation. To minimize handling time during the 
RNA extraction procedure, samples were processed in 
small batches of 4. After thawing for 30 min. at room tem-
perature each sample was poured into 50 ml Falcon conical 
tube (BD) and 3 ml of 95% molecular biology grade etha-
nol (Applichem) was added. The mixture was intensively 
vortexed on high speed for 5 min. and then centrifuged at 
5200×g for 60  min at 0 °C. The foaming and the super-
natant were poured off and the rim of the inverted Falcon 
tube was blotted on clean absorbent paper for 1 min. 500 µl 
of lysis solution supplemented with 5  µl of TCEP solu-
tion from PerfectPure™ RNA Cell and Tissue (5 Prime) 
was added and RNA pellet was dissolved by vortexing for 
1 min. The lysate was pipetted onto a purification column 
(5 Prime). All other procedures including successive cen-
trifugations, washing steps, DNase treatment and RNA elu-
tion were according to PerfectPure™ RNA Cell & Tissue 
manual except prolonged to 45  min. On column DNase 
digestion at room temperature. Purified RNA concentra-
tion, purity, and integrity were determined by A260, A280 
and A230 measurements using a NanoDrop ND1000 Spec-
trophotometer (NanoDrop Technologies) and Agilent 2100 
Bioanalyzer with Agilent RNA 6000 Nano Kit (Agilent 
Technologies). The remaining samples were aliquoted and 
stored at −80 °C until use.
Oligonucleotide microarray, aRNA synthesis 
and labelling, microarray experimental design, 
hybridization, and image acquisition
The bovine microarray platform used was Bovine Long 
Oligo Extension (BLOPlus), a 10  K spotted 70-mer oli-
gonucleotide microarray (GEO platform accession: 
GPL9176), manufactured and purchased from Center for 
Animal Functional Genomics, Michigan State University. 
Cy3/Cy5 dye (GE Healthcare) labelled, linearly amplified, 
antisense aRNA was generated from 1 µg of each sample 
total RNA using Amino Allyl MessageAmpTMII aRNA 
Amplification kit (Ambion, Life Technologies) accord-
ing to the manufactures’ instructions. The quantity and the 
quality of the resulting aRNA was analysed by spectropho-
tometry and and Agilent 2100 Bioanalyzer with Agilent 
RNA 6000 Nano Kit (Agilent Technologies). The amount 
of fluorescent dye incorporated into aRNA was measured 
as its absorption at 550 nm (Cy3) and 650 nm (Cy5) using 
a NanoDrop ND1000 Spectrophotometer MicroArray built-
in module (NanoDrop Technologies). Preliminary micro-
array dyE−swap experiments were performed in order to 
optimize the conditions of microarray hybridization, wash-
ing and scanning protocol. Afterwards a common reference 
design was employed for microarray hybridizations, thus all 
the aRNAs were labelled with Cy5 and co-hybridized with 
Cy3 labelled common reference pool aRNA. The common 
reference aRNA pool was set up by mixing equal amounts 
of total RNA from all samples in the study and pooled 
RNA was subsequently used for aRNA linear amplifica-
tion. Twenty-four arrays were hybridized, representing 12 
BLV-infected and 12 non-infected cows. For each micro-
array slide 60 pmol of Cy5 labelled aRNA was combined 
with 60  pmol of Cy3 labelled common reference aRNA 
(5–10  μl of total volume) diluted with SlideHyb#1 glass 
array hybridization buffer (Ambion, Life Technologies) 
up to 130 μl and denatured at 70 °C for 5 min. Microarray 
hybridizations were carried out using a Tecan HS400 Pro 
hybridization station (Tecan) according to following proto-
col: step 1 (wash) −70 °C, runs 1, wash time 10 s, soak time 
20  s; step 2 (sample injection) −70 °C; step 3 (hybridiza-
tion) −42 °C/6 h, 35 °C/6 h, 30 °C/6 h with medium agita-
tion frequency; step 4 (wash) 37 °C, runs 5, wash time 10 s, 
soak time 20 s (2 × SSC, 0.1% SDS) (Ambion, Life Tech-
nologies), 25 °C, runs 5, wash time 10  s, soak time 20  s 
(0.2 × SSC, 0.1% SDS), 25 °C, runs 5, wash time 10 s, soak 
time 20  s (0.2 × SSC); step 5 (N2 slide drying) 25 °C for 
2  min. Immediately afterwards microarrays were scanned 
using a ProScanArray device and ScanArray Express image 
acquisition and analysis software (Perkin-Elmer).
Microarray data processing, normalization and analysis
The linear models for microarray data (LIMMA, [45]) 
software was used to identify differential gene expres-
sion. Background correction was performed and within 
microarray print-tip LOWESS (locally weighted scat-
terplot smoothing) normalization was employed. No 
between array normalization was needed (data not shown). 
For each gene spot, t-statistic, B-statistic, M value (log2 
[Cy5/Cy3]), A value (1/2 [log2 Cy5 + log2 Cy3]) were 
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calculated. Probability p values were corrected for multiple 
testing using the false discovery rate (FDR) [5]. An arbi-
trary fold change of FC ≥1.5 (represented by −0.585 ≤ M 
value ≥ 0.585) and FDR-adjusted (adj. p ≤ 0.01) signifi-
cantly differentially expressed (DE) genes were subjected 
to meta-analysis using a web-based GeneGo MetaCore™ 
analytical suite (ver. 5.3, GeneGo, Thomson Reuters). The 
uploaded list of DE gene IDs was submitted to gene ontol-
ogy (GO) over-representation analysis including functional 
categories: GO Processes, GO Molecular Functions, GO 
Localizations, GeneGo Process Networks and GeneGo Dis-
eases. The in silico predicted functional protein networks 
were generated using the Analyze Networks (AN) build-
in algorithm. Additionally, a list of transcription factors 
related to the expression regulation of DE genes was con-
ceived by AN Transcription Regulation algorithm.
Validation of microarray results by real-time qRT-PCR
The validation of gene expression data was performed by 
qRT-PCR for 14 genes (up-regulated, down-regulated and 
with no regulation according to microarray data) using a 
LightCycler® LC 480 II system (Roche). For each target 
gene a total of 24 experimental cDNA samples in duplicate 
(from 12 BLV+ and 12 BLV− individuals) and a triplicate 
of no template control (NTC, molecular grade water) were 
amplified. All procedures including cDNA synthesis, prim-
ers design, PCR reaction set up, cycling conditions, melt-
ing curve analysis, amplicon’s size and specificity control, 
standard curve preparation, PCR efficiency (E) and Error 
value calculation and quantification cycle (Cq) determina-
tion were performed as in [6].The primers and the target 
amplicons information are presented in Table 4. For qRT-
PCR data normalization, a pair of RPLP0 and UCHL5 was 
employed, as the most stable reference genes for this exper-
iment, based on a previous determination from a panel of 
10 putative reference gene candidates [6]. The gene expres-
sion differences between BLV-infected and BLV uninfected 
groups were estimated with Relative Expression Software 
Tool REST 2009 V2.0.13 [37].
Results
Microarray analysis of differentially expressed genes 
in blood cells of naturally BLV-infected and uninfected 
Holstein cattle
To better understand the role of the genes involved in the 
host response to BLV infection and BLV-induced lym-
phoproliferation and malignant transformation, we per-
formed gene expression profiling of BLV-infected and 
uninfected Holstein cattle. The applied microarray platform 
comprised the two-color, 70-mer oligonucleotide spot-
ted Bovine Long Oligo Plus (BLOPlus, 10  K) array and 
the obtained data was deposited in NCBI Gene Expres-
sion Omnibus with accession no. XXXXXX. An analy-
sis of mRNA abundance in blood samples from 12 BLV 
infected cattle and 12 non-infected controls was per-
formed. The BLV infected group comprised animals ca. 
5 years old, seropositive with apparent hematological 
abnormalities (Table  1). Due to the strict BLV eradica-
tion policy in Poland, we were able to blood sample the 
BLV-positive individuals only once, so we could not offi-
cially categorize them as in the persistent lymphocytosis 
(PL) stage of disease. However, the high total lymphocyte 
counts (15.16 ± 10.28 × 103/μl, Table  1), high total white 
blood cell counts (WBC), high titers of antibodies against 
p24 and gp51 and qualitative estimation of BLV proviral 
loads by PCR products densitometry analysis [29], (data 
not shown) indicated that this certainly was the case. The 
BLV-uninfected control group comprised cows of the same 
breed, similar age (Table 1), diagnosed as BLV-negative by 
both serological and molecular approaches. It is of inter-
est to emphasize the fact that all the studied BLV-nega-
tive animals were housed for at least 3 years in the same 
2 BLV-positive herds as their BLV-infected counterparts. 
Nevertheless they did not become infected. As resistance 
and susceptibility are opposite sides of the same coin, it is 
tempting to treat the BLV-negative group not only as the 
control group, but also to reverse the microarray scheme 
and to suspect the BLV-negative animals as constituting 
some degree of innate resistance to BLV infection. Because 
of the critical dependence of gene expression measure-
ments on starting RNA quality, we included in our analy-
sis only samples which were marked by high RNA quality 
indices, and without any significant differences between the 
compared groups (Table 1).
Table 1  Comparison of total lymphocyte counts, age of the animals 
and RNA quality indices in cows analyzed in the study classified to 
BLV infected and healthy groups based on ELISA and nested-PCR 
tests






x̀ SD x̀ SD
Lymphocytes × 103/µl 15.16a 10.28 3.43a 1.22
Age (year) 5.23 0.81 4.88 0.58
RNA quality
 A260/A280 2.08 0.022 2.08 0.027
 RIN 9.16 0.59 9.04 0.49
 28S/18S 1.97 0.51 1.79 0.33
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A total of 24 microarrays were hybridized, scanned 
and analyzed using a common reference experimental 
design. With an arbitrary cut-off value of 1.5 fold change 
(FC) in gene expression, we identified the down-regula-
tion of 212 genes (M value ≤−0.585) and the up-regu-
lation of 158 genes (M value of ≥0.585) at a 1% false 
discovery rate in BLV-positive animals in comparison to 
the BLV-negative group. The maximum value of down-
regulation (FC = −3.21) was noted for two genes S100A4 
(S100 Calcium-Binding Protein A4, formerly known as 
MTS1 or Metastasin) and CFD (Complement Factor D, 
formerly known as Adipsin). The most up-regulated gene 
(FC = 3.18) in blood cells from BLV-positive in com-
parison to BLV-negative cows was ADRA2A encoding 
Adrenoceptor Alpha 2A, a member of the G protein-cou-
pled receptor superfamily. Lists of the top 25 down- and 
up-regulated genes in BLV-infected vs BLV-uninfected 
groups classified according to decreasing statistical sig-
nificance of gene expression estimation (B-statistics) are 
presented in Tables  2 and 3 respectively. The complete 
lists of 212 and 158 DE genes are presented in the sup-
plemental files (Tables  2S and 3S). Hierarchical clus-
tering HCL heatmap for 370 differentially expressed 
genes and 24 samples (12 BLV-infected vs 12 BLV non-
infected) analyzed in the study is presented in the supple-
mentary Fig. 6S. Assuming gene expression fold changes 
FC ≥2 and FC ≥1.75 at p value (FDR-adjusted) <0.01 we 
were able to identify 33 and 70 up-regulated genes and 
almost twice as many down-regulated genes (64 and 130, 
respectively) in BLV-infected cattle in comparison to 
the control group. These values indicated that low (~1.5 
fold) and medium (≥1.75 fold) gene expression changes 
were the most abundant classes, characteristic for BLV-
induced progression to the lymphocytotic stage of the 
disease. The higher number of down-regulated genes than 
up-regulated ones may reflect the viral latency state, typi-
cal for the majority of BLV-infected cells in vivo and/or 
the evasion of the host’s immune surveillance.
Table 2  The list of top 25 down-regulated genes in BLV-infected cattle in comparison to BLV-negative group
Oligo_id Gene symbol Gene Ref. seq Fold change p value FDR adj. B stat.
Bt00001447 CFD Complement factor d (adipsin) NM_001034255 −3.21 1.743E−10 22.5
Bt00007539 ITCH Itchy E3 ubiquitin protein ligase homolog (mouse) NM_001082428 −2.30 1.722E−07 14.1
Bt00007239 CD63 CD63 molecule NM_205803 −2.57 1.722E−07 13.9
Bt00000825 AIF1 Allograft inflammatory factor 1 NM_173985 −3.13 2.151E−07 13.6
BLO_ext_00163 F5 Coagulation factor V (proaccelerin, labile factor) NM_173879 −2.50 2.744E−07 13.2
Bt00005024 S100A4 S100 calcium binding protein A4 NM_174595 −3.21 3.990E−07 12.8
Bt00002294 LGALS1 Lectin, galactosidE−binding, soluble, 1 NM_175782 −2.79 7.355E−07 12.0
Bt00005520 SLC40A1 Solute carrier family 40 (iron-regulated trans-
porter), member 1
NM_001077970 −2.24 1.479E−06 11.2
BLO_ext_00934 SIRPA Signal-regulatory protein alpha NM_175788 −2.78 1.921E−06 10.9
Bt00002021 CST3 Cystatin C NM_174029 −1.83 2.586E−06 10.5
BLO_ext_00656 LGMN legumain NM_174101 −2.02 5.908E−06 9.5
Bt00004059 NFAM1 NFAT activating protein with ITAM motif 1 XM_002687969 −2.24 8.704E−06 9.1
BLO_ext_01819 CEBPA CCAAT/enhancer binding protein (C/EBP), alpha NM_176784 −2.32 9.307E−06 9.0
Bt00007592 PLA2G7 Phospholipase A2, group VII (platelet-activating 
factor acetylhydrolase, plasma)
NM_174578 −2.28 9.668E−06 8.9
BLO_ext_00486 CD2 CD2 molecule NM_001011676 −2.21 9.766E−06 8.8
Bt00003322 STAT4 Signal transducer and activator of transcription 4 NM_001083692 −1.95 9.766E−06 8.8
Bt00002910 TGFBI Transforming growth factor, beta-induced, 68 kDa NM_001205402 −2.71 1.164E−05 8.6
Bt00007971 AMICA1 Adhesion molecule, interacts with CXADR antigen 
1
NM_001080250 −2.13 1.243E−05 8.5
Bt00001417 PLA2G16 Phospholipase A2, group XVI NM_001075280 −1.89 1.530E−05 8.3
Bt00003194 MTMR9 Myotubularin related protein 9-like NM_001046256 −2.26 1.673E−05 8.1
BLO_ext_00190 TYROBP TYRO protein tyrosine kinase binding protein NM_174627 −2.54 1.833E−05 8.0
Bt00007151 ANXA3 Annexin A3 NM_001035325 −1.81 1.872E−05 7.9
Bt00007329 LGALS3 Lectin, galactosidE−binding, soluble, 3 NM_001102341 −1.89 2.056E−05 7.8
BLO_ext_01078 CAPN2 Calpain 2, (m/II) large subunit NM_001103086 −1.83 2.220E−05 7.7
Bt00003792 ITGB7 Integrin, beta 7 NM_001105365 −1.93 2.363E−05 7.6
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Validation of the microarray results by real-time 
qRT-PCR method
The accuracy of gene expression estimations from the 
microarray analysis was validated by the real-time qRT-
PCR method. The analysis was performed on blood 
samples from the same 24 animals used in microarray 
analysis, although the technical replicate of RNA iso-
lation was used for the reverse transcription reaction. 
A total of 14 genes were studied including 8 genes 
down-regulated according to microarray results (i.e.: 
CFD, ITCH, S100A, LGALS, TGFBI, CXCL8, DAP12, 
and C/EPB alpha, Table  2) and 4 up-regulated genes 
(i.e. MS4A1, HIF1A, MSH2 and ADAM9, Table  3) 
in the BLV-infected group in comparison to the BLV-
uninfected animals. Additionally, two genes with no 
differential expression between the studied groups were 
randomly selected, i.e. LTB encoding lymphotoxin beta 
(fold change, FC = −1.02, p value FDR adjusted = 0.929) 
and BNIPL encoding B-cell lymphoma (BCL2)/ade-
novirus E1B 19kD interacting protein (fold change, 
FC = 1.2, p value FDR adjusted = 0.36). For qRT-PCR 
data normalization, a pair of RPLP0 and UCHL5 gene 
was employed, based on stable expression in BLV-
infected leucocytes which was determined previously 
[6]. The target amplicons information is presented in 
Table  4, and their specificity was confirmed by DNA 
sequencing (data not shown). The relative gene expres-
sion measurements between the BLV-infected and the 
BLV-uninfected groups were estimated with REST 2009 
software (Fig.  1a) and indicated significant differences 
in gene expression levels in all analyzed genes except 
Table 3  The list of top 25 up-regulated genes in BLV-infected cattle in comparison to BLV-negative group
Oligo_id Gene symbol Gene Ref. seq Fold change p value FDR adj. B stat.
Bt00004943 MSH2 MutS homolog 2, colon cancer, nonpolyposis 
type 1 (E. coli)
NM_001034584 2.25 7.54E−09 18.5
Bt00004141 KBTBD8 T cell activation kelch repeat protein NM_001192696 2.66 1.78E−08 17.3
Bt00006375 ADRA2A Alpha2A adrenergic receptor NM_174499 3.18 2.39E−08 16.8
BLO_ext_00185 MS4A1, CD20 MembranE−spanning 4-domains, subfamily A, 
member 1
NM_001077854 2.95 2.39E−08 16.6
BLO_ext_00550 ADORA2B Adenosine A2b receptor NM_001075925 2.38 8.08E−08 15.3
Bt00002242 PPA2 Pyrophosphatase (inorganic) 2 NM_001076396 2.16 1.34E−07 14.7
Bt00000295 CD19 CD19 molecule NM_001245998 2.12 1.58E−07 14.3
BLO_ext_00374 APEX1 APEX nuclease (multifunctional DNA repair 
enzyme) 1
NM_176609 2.05 1.58E−07 14.3
Bt00000725 HIF1A Hypoxia inducible factor 1, alpha subunit (basic 
helix-loop-helix transcription factor)
NM_174339 2.56 1.72E−07 14.0
BLO_ext_01490 SLC4A10 Solute carrier family 4, sodium bicarbonate 
transporter-like, member 10
NM_001038128 3.05 2.27E−07 13.5
Bt00006625 CCT5 T-complex protein 1, chaperonin containing 
TCP1, subunit 5 (epsilon)
NM_001034595 1.75 2.48E−07 13.4
Bt00005595 SH3GLB2 SH3-domain GRB2-like endophilin B2 NM_001076802 2.13 4.43E−07 12.6
Bt00001908 LMO2 LIM domain only 2 (rhombotin-like 1) NM_001076352 2.16 4.43E−07 12.6
Bt00007026 CCNG1 Cyclin G1 NM_001013364 1.97 6.94E−07 12.1
Bt00003454 BANK1 B-cell scaffold protein with ankyrin repeats 1 XM_002688119 1.78 7.36E−07 12.0
Bt00004115 HADH Hydroxyacyl-CoA dehydrogenase NM_001046334 2.15 1.22E−06 11.4
BLO_ext_01117 HSD17B4 Hydroxysteroid (17-beta) dehydrogenase 4 NM_001007809 2.39 1.59E−06 11.1
BLO_ext_00320 DYNLL1 Cytoplasmic dynein light polypeptide 1 NM_001003901 2.02 1.97E−06 10.8
Bt00006382 SIRT5 Sirtuin 5 NM_001034295 1.98 2.41E−06 10.6
Bt00000583 C1QBP Complement component 1, q subcomponent 
binding protein (C1QBP), nuclear gene encod-
ing mitochondrial protein
NM_001034527 1.99 3.03E−06 10.3
Bt00002141 GMPS Guanine monphosphate synthetase BC111273 1.77 4.24E−06 9.9
Bt00003030 HSD17B10 Hydroxysteroid (17-beta) dehydrogenase 10 NM_174334 1.86 4.61E−06 9.8
Bt00003407 TRMT112 tRNA methyltransferase 11 − 2 homolog (S. 
cerevisiae)
NM_001045981 1.85 4.61E−06 9.8
Bt00004269 SRSF9 Serine/argininE−rich splicing factor 9 NM_001083398 1.77 5.91E−06 9.5
BLO_ext_00630 zfp106 Zinc finger protein 106 homolog (mouse) XM_002690810 2.08 9.57E−06 8.9
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LTB and BNIPL (p values: 0.46 and 0.11 respectively). 
The calculated fold changes were log2-transformed and 
compared with log2 M-values from microarray analy-
sis. The regression line among the results from differ-
ent methods is described by the equation: log2FC-qRT-
PCR = −0.39 + 1.02 × log2FC-microarray, with Pearson’s 
correlation coefficient (r) equaling 0.98 (Fig.  1b). The 
high value of the correlation coefficient holds out the 
hope that the rest of the gene expression measurements 
on the microarray are also valid.
Gene set enrichment analysis of DE gene lists generated 
from the microarray experiment
To improve the amount and the quality of the ontologi-
cal information, a total of 370 DE genes identified with 
the BLOPlus microarray were updated in annotation 
terms and gene IDs using probe sequence information 
and BLAST analysis. The list of updated gene IDs and 
the expression data were input into online meta-analysis 
(A)
(B)























Fig. 1  Real-time qRT-PCR validation of microarray results. a 
Whisker-box plots of relative expression values for 14 genes in BLV-
infected group in comparison to non-infected control. The median 
of gene expression is depicted by the dotted line. Whiskers and box 
show the minimum and maximum values and the interquartile range 
of observations, respectively. b Correlation plot between fold-change 
(FC) differences revealed by gene expression measurement methods 
(microarray vs. qRT-PCR). The regression line among the results 
from different platforms is described by equation: log2FC-qRT-
PCR = −0.39 + 1.02 × log2FC-microarray, with Pearson’s correlation 
coefficient (r) equals 0.98
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software GeneGo MetaCore™ analytical suite (ver. 5.3, 
GeneGo, Thomson Reuters).
First, public gene ontology (GO) categories, i.e. GO 
Processes (biological process), GO Molecular Functions 
and GO Localizations (cellular component) were assessed, 
by that disclosing the biological motifs associated with the 
expression differences observed. The results indicated that 
the genes with differential expression (DE) could be clas-
sified to the numerous gene ontology terms, although with 
a substantial level of overlapping and redundancy (Fig. 2a, 
c, d). The enrichment analysis reports, including the top-
100 GO terms with calculated p value, FDR and the list of 
genes involved in each GO term, are presented in the sup-
plementary MS Excel files (Tables 5S, 6S, 7S). Excluding 
some overlapping terms, we were able to select diverse bio-
logical process categories, significantly affected by BLV-
infection and the host response, such as: immune system 
process, response to stress and wounding, regulation of 
immune response, cell activation, innate immune response, 
coagulation, regulation of programmed cell death, regula-
tion of metabolic processes, regulation of cell commu-
nication, regulation of signal transduction, regulation of 
cell proliferation, and DNA repair. In addition, the more 
detailed GeneGo Process Networks Ontology, based on a 
manual curation database (MetaCore™ ver. 5.3, GeneGo, 
Thomson Reuters), further delineated the most affected 
processes and functional networks, among others: inflam-
mation in particular NK-cell cytotoxicity, complement sys-
tem, IL-2, TREM-1 and protein C signaling; cell adhesion 
and chemotaxies; immune response in a particular phago-
some at antigen presentation, Th-17 derived cytokines, 
TCR signaling; apoptosis and signal transduction (TGF-
beta, GDF, activin and leptin signaling) (Fig. 2b and sup-
plemental MS Excel Table  8S). Among GO molecular 
functions the most abundant category was represented by 
protein binding (Fig. 2c). On the other hand, GO Localiza-
tions enrichment analysis pointed to the importance of the 
extracellular region in BLV-induced pathogenesis (Fig. 2d).
Furthermore, the gene set enrichment analysis by 
GeneGo Disease Biomarkers Ontology linked the genes 
down-regulated in BLV-positive individuals with, among 
others: connective tissue diseases, numerous autoim-
mune diseases, viral diseases and lymphoma. In contrast, 
the genes with up-regulated expression in PL animals 
were connected with, as expected lymphoma, non-Hodg-
kin’s lymphoma, numerous neoplasms, and, unexpectedly 
schizophrenia and mental disorders (Fig. 3a, b). Although 
we used in our comparisons animals similar to PL, which is 
thought to be a benign, preneoplastic stage of the disease, a 
total of 87 genes from our DE data set was linked with lym-
phoma and an even greater number of genes were linked 
with biomarkers of the neoplastic transformation of differ-
ent organs. It may be suggested that deregulation of not a 
few but rather multiple genes established the transcriptional 
foundation of the initial transformation events induced by 
BLV towards a leukemogenesis. In addition, the observed 
enrichment of the genes associated with autoimmune dis-
eases, sheds light on a new possible mechanism contribut-
ing to a failure of the host immune response against BLV.
We used the Analyzed Networks (AN) Transcription 
Regulation algorithm from MetaCore™ to identify the 
transcription factor (TF) pathways and networks that regu-
late the processes associated with BLV-induced pathogen-
esis. The AN Transcription Regulation algorithm revealed 
a list of 30 TFs potentially involved in the expression of 
differences observed in our study, including: CREB1, 
c-MYC, SP1, NF-κB, GCR-alpha, c-JUN, ETS1, C/EBP, 
p53, STAT1, STAT3 and HIF1A (supplementary MS Excel 
Table  9S). The three most connected factors: CREB1, 
c-MYC and SP1 regulate more than 50% of the genes in 
our DE data set. The CREB1 network (Fig.  4) illustrates 
CREB1 with its 159 targets (proteins regulated by CREB1) 
functioning in different areas of the cell. It should be 
emphasized that the BLV transactivator protein Tax binds 
and cooperates with the CREB transcription factor, and 
the former is one of the main targets of the Tax protein. Of 
note, transcription factors HIF1A (Fig.  5), C/EBP alpha, 
c-JUN (AP-1) which regulate the expression of many genes 
in our data, are simultaneously the targets for gene expres-
sion deregulation induced by BLV infection and the disease 
progression to the PL stage.
Discussion
In this study we used oligonucleotide bovine specific BLO-
Plus microarrays and qRT-PCR analysis to examine gene 
expression changes in blood cells in response to retrovi-
ral BLV infection and disease progression to the lympho-
cytotic stage. Subsequently, the identified differentially 
expressed genes were used in the gene enrichment meta-
analysis approach to reveal biological patterns associated 
with the expression differences observed. Before discuss-
ing the major items revealed by our study, we would like to 
emphasize the particular context of the obtained results. (1) 
The analysis of mRNA abundance between the naturally 
BLV-infected cattle and non-infected controls was per-
formed on whole blood transcriptomes, using a dedicated 
tube system, which allowed for immediate cell lysis after 
Fig. 2  Enrichment analysis of differentially expressed genes identi-
fied in this study. Bar length indicates the significance and equals to 
the negative logarithm of enrichment p value. a Top 20 significant 
biological processes from GO ontology. b Top 20 significant process 
networks from MetaCore ontology. c Top 20 significant molecular 
functions from GO ontology. d Top 20 significant localization (cel-
lular compartments) from GO ontology
◂
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Fig. 3  Enrichment analysis of differentially expressed genes identi-
fied by disease biomarkers (GeneGO). Bar length indicates the sig-
nificance and equals to the negative logarithm of enrichment p value. 
a Diseases associated with the genes down-regulated in BLV-infected 
cattle in comparison to non-infected controls. b Diseases associated 
with the genes up-regulated in BLV-infected cattle in comparison to 
non-infected controls
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Fig. 4  CREB Network. The CREB network shows the CREB tran-
scription factor (enclosed by black circle) as a hub controlling the 
expression of proteins which are encoded by genes from the DE gene 
list. The various symbols used in the network have been described in 
detail in MetaCore Quick Reference Guide file publicly available at: 
https://portal.genego.com/help/MC_legend.pdf
Fig. 5  HIF1 Network. The HIF1 network shows the HIF1 transcrip-
tion factor (enclosed by black circle) as a hub controlling the expres-
sion of proteins which are encoded by genes from the DE gene list. 
The various symbols used in the network have been described in 
detail in MetaCore Quick Reference Guide file publicly available at: 
https://portal.genego.com/help/MC_legend.pdf
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bleeding, and the stabilization of received mRNAs with 
RNA stabilization solution. In contrast, most of the gene 
expression data, analyzed in the context of BLV studies 
and reported previously [22, 23, 50], were generated with 
peripheral blood mononuclear cells (PBMC) separated 
by density gradient centrifugation. As we also collected 
blood samples into tubes with EDTA, we endeavored to 
isolate total RNA also from buffy coats and PBMCs pre-
pared with the standard Ficoll-Hypaque method. Probably 
due to the prolonged time required for blood collection 
and transport from dairy farms to the laboratory, exceed-
ing 24 h, these methods resulted in partially degraded RNA 
with highly variable indices of RNA quality (RIN values 
ranging from 3.2 to 7.8, data not shown), which was not 
suitable for reliable gene expression analysis. In contrast, 
Tempus™ Blood RNA Tube technology allowed for RNA 
isolation with yields sufficient for microarray analysis and 
the RNA quality parameters indicating negligible RNA 
degradation between the groups in comparison (Table  1). 
In addition to RNA degradation, the reliability of gene 
expression estimations of many immunologically important 
genes (including those mentioned in the context of BLV 
response, like TNFα, IL6, IL10, IL12, IFNγ, NFκB, IκB) is 
significantly affected by unintended gene regulation caused 
by phlebotomy [35], sample handling, [47], and uncon-
trolled activation of coagulation [39]. Furthermore, in vivo 
BLV is latent in the majority of infected cells, however, 
expression of BLV in samples of whole blood from BLV-
infected animals is activated immediately upon incubation 
at 37 °C in the absence of any exogenous factors, except for 
anticoagulants or the removal the blood cells from plasma 
[13, 46]. Consequently, an exaggerated immune response, 
based on differential mechanisms, could happen ex vivo in 
comparison to in vivo processes. Preservation of the blood 
transcriptomes in Tempus Blood RNA tubes or similar 
PAXgene tubes restricts ex  vivo gene expression, allow-
ing meaningful RNA assays and yielding transcript con-
centrations that are much closer to in vivo responses than 
can be obtained by other methods [39]. Nevertheless, the 
drawback of the whole blood transcriptome preservation 
approach is the fact that it is not possible at this time to dis-
tinguish which genes are deregulated because of their pri-
mal, direct participation in the host-pathogen interactions 
and which genes are affected as the result of secondary 
effects of BLV infection, such as the hematological profile 
alteration. Further investigations of selected genes reported 
in this study and involved in particular biological process of 
interest are needed to determine which molecular pathways 
result in BLV infection and disease progression and which 
are a result of BLV infection and disease progression. (2) 
The absence of clinically diagnosed lymphoma individuals 
that have been monitored in Poland in recent years and the 
comparatively high prevalence of animals with persistent 
lymphocytosis implied that a benign nonmalignant PL 
could be a convenient disease stage for the microarray 
analysis of host genetic factors that affect the outcome of 
BLV-infection. Lately, a strict BLV eradication policy has 
been implemented in Poland, and has resulted in the almost 
complete eradication of this previously highly endemic 
infectious agent. Newly diagnosed BLV seropositive indi-
viduals are eliminated from the herds immediately, and 
sometimes all animals within the herd (both seropositive 
and seronegative) are subjected to the compulsory slaugh-
ter. That is why we were able to collect blood samples from 
the BLV-positive individuals only once, so we could not 
examine the persistency of hematological aberrations and 
officially categorize them as the persistent lymphocytosis 
stage. However, the high total lymphocyte counts (mean 
15.16 ± 10.28 × 103/μl, Table  1), high total WBC counts, 
high titers of antibodies against p24 and gp51 and qualita-
tive estimates of the proviral load (data not shown) [1, 16, 
29] characterized all the animals within the BLV-positive 
group and indirectly indicated that all of them were PL.
The global gene expression data related to BLV-induced 
pathogenesis are relatively limited. To our knowledge, 
four research groups employed microarray technology to 
address potential gene expression alterations in host cells 
induced by BLV [4, 12, 22, 50]. In general, the lists of dif-
ferentially expressed genes reported in these studies coin-
cide sparsely with each other. A similar trend is also appar-
ent when we compare the DE genes identified in this study 
with the previous reports. There are only a few DE genes 
in common between the lists (e.g. MHC class II-DOB, 
HAT1 encoding histone acetyltransferase 1, APEX1 encod-
ing multifunctional DNA repair enzyme, CCNG1 encod-
ing cyclin G1), a few DE genes with invert expression (e.g. 
JUN oncogene, MAFB encoding v-maf musculoaponeu-
rotic fibrosarcoma oncogene homolog B), and a number of 
differentially expressed genes encoding members of closely 
related gene families with overlapping molecular functions 
(e.g. ATF-activating transcription factor family of basic 
leucine zipper protein members, LMO-LIM domain only 
family members of transcription regulators, DUSP-dual 
specificity phosphatase family members). The relatively 
small coincidence between the lists of DE genes among 
the analyzed reports should not be surprising, taking into 
account that different experimental designs were applied in 
each case. In three studies, transformed and immortalized 
cell lines were used, including human epithelial HeLa cells 
[4] and ovine jejunal Peyer’s patch-derived B-cell clone 
[22], which were subsequently transfected with plasmid 
vectors containing TaxBLV, in order to identify the spectrum 
of host genes regulated by Tax. In the latter, PBMC derived 
sheep B-cells cultured in  vitro were also analyzed. In the 
third study [12] and its follow-up with siRNA knock-down 
of BLV Tax [34], the transcript profiling of a transformed 
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but uninfected bovine lymphoblastoid cell line BL3o was 
performed in comparison to its in vitro BLV-infected deriv-
ative cell line BL3*. However, no details about the identity 
of DE genes were presented in either report. On the other 
hand, the genes up-regulated in PBMC from 3 PL cows, 
cultured with purified plasma blocking factor, as compared 
with those cultured in medium were shown [50]. Further-
more, different microarray platforms were applied, includ-
ing singlE−color human specific Affymetrix chips [4], two-
color human specific cross species microarray approaches 
[22, 50], and the two-color bovine specific 7  K cDNA 
microarray [12]. In contrast, this study presents a compari-
son of the blood transcriptomes between naturally BLV-
infected cattle and uninfected controls, captured immedi-
ately after bleeding without cell culturing and performed 
with the bovine specific microarray platform.
In our data we noted the interesting phenomenon that 
BLV infection and disease progression to PL is associated 
with higher numbers of down-regulated genes than up-
regulated ones (58% with FC ≥1.5 increasing to 65% when 
only FC ≥1.75 were considered). We hypothesize that, this 
may reflect the viral latency state, typical for the majority 
of BLV-infected cells in  vivo and/or it may characterize 
BLV-induced immunosuppression, leading to the failure of 
an efficient immune response and underlying the host’s eva-
sion mechanism developed by BLV during evolution. The 
opposite result, with the dominance of up-regulated genes 
(exceeding 70–80% of total DE genes), was reported in 
in vitro cultured cells induced by the BLV Tax protein [4, 
22]. Such a redeployment towards gene induction is typical 
for many transcriptional profiles drawn from experiments 
utilizing in vitro cultures and purified factors in the study, 
dosed frequently with non-physiological ranges [9, 19, 50]. 
On the other hand, the results of the transcriptome profil-
ing of blood cells from cattle naturally infected with patho-
gens like Mycobacterium bovis, Mycobacterium avium ssp. 
paratuberculosis, or Trypanosoma congolense, associated 
with chronic diseases, clearly demonstrated the importance 
of the gene repression mechanisms during the pathogenesis 
in  vivo, which was reflected by the higher number of the 
down-regulated genes [21, 31, 33, 51]. The range of gene 
expression changes identified in our data set, with a maxi-
mum down- and up-regulation fold change factor of around 
3.2, indicated that BLV-induced progression to the PL stage 
of the disease was associated mainly with low (FC ~1.5) 
and moderate (FC ≥1.75) gene expression changes, with 
only rare examples of high levels of differential expression 
(FC ≥3). A similar picture of primarily small and moder-
ate gene expression changes emerged from the analysis of 
ovine B-cells transfected with the Tax containing vector 
[22]. Likewise, among 122 genes deregulated by the wild-
type Tax protein only 10 showed differential expression 
exceeding fourfold, with the rest of the gene expression 
changes within the range of 2–3 fold [4]. Apart from genes 
with high levels of differential expression, those exhibiting 
low differences could be of peculiar concern, taking into 
account that small changes in gene expression are supposed 
to be adequate to disturb cell homeostasis [22].
Our expression data support the importance of DNA 
repair processes during BLV-induced leukemogenesis. 
Philpott and Buehring reported that in the immortalized 
and transformed cell lines infected by the HTLV/BLV 
group of retroviruses [38], Tax inhibits basE−excision 
DNA repair of oxidative damage, thereby potentially induc-
ing genomic instability and increasing the accumulation of 
mutations in cellular DNA. Of note, we found an increased 
expression of APEX1 (also known asAPE1/Ref1) mRNA 
in the BLV-infected group (+2.05-fold, p = 1.58E−07). 
APEX1 encodes a multifunctional protein engaged in the 
DNA base excision repair (BER) pathway of oxidative 
DNA damage (apurinic/apyrimidinic-endonuclease activ-
ity), as well as in transcriptional regulation. The latter is 
achieved as a redox coactivator of many transcription fac-
tors (among others: AP-1, Egr-1, NF-κB, p53, and HIF), 
and by its ability to indirectly bind to the negative calcium 
response elements (nCaRE) of some promoters acting as 
a transcriptional repressor [2, 48]. The up-regulation of 
APEX1 mRNA was also reported in sheep B lymphocytes 
transfected with Tax-containing vector [22], and in tumor 
tissues and cancer cells of diverse origin [48], and its over-
expression is associated with tumor cells’ resistance to 
various anticancer drugs [44]. The necessity of APEX1 for 
cellular survival and its frequent overexpression in tumor 
cells strongly suggest a fundamental role of this protein in 
preventing cell death and in controlling cellular prolifera-
tion [48], probably through its regulatory role in the expres-
sion of cyclin-dependent kinase inhibitor p21 (CDKN1A) 
[44] and in the DNA binding activity of the p53 protein [7]. 
Furthermore, we found MSH2 (MutS homolog 2) encod-
ing an important component of the post-replicative DNA 
mismatch repair system (MMR) as the most significantly 
upregulated gene in the BLV-infected group (+2.25-fold, 
p = 7.54E−09, Table  3). MutSα may also play a role in 
DNA homologous recombination repair, and may modulate 
cell cycle regulation and apoptosis. Defects of MSH2 are 
implicated in the development of lymphoblastic lympho-
mas in humans and mice, and are associated with the aber-
rant expression of the LMO2 (LIM domain only 2) gene 
[28], encoding a transcription factor which has a central 
and crucial role in hematopoietic development and neo-
plastic transformation. It is of interest that we also observed 
an increase in the expression of LMO2 gene (+2.16-fold, 
p = 4.43E−07) in BLV-infected animals in comparison to 
the BLV-negative control group. In vitro studies indicated 
that genetic instability associated with the downregulat-
ing of MutSα alpha is induced by the HIF-1A transcription 
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factor (Hypoxia inducible factor-1α) [24]. Hypoxia-oxygen 
deficiency in tissues is a key factor in the tumor microen-
vironment that has been tightly associated with tumor pro-
gression, metastasis and resistance to therapy [24] due to 
the increased rate of mutations in hypoxic conditions. We 
detected a significant over-expression of HIF-1A (+2.56-
fold, p = 1.58E−07) in the BLV-positive group and our 
meta-analysis identifies an HIF1A network (Fig.  5) with 
the HIF1A protein as a hub with multiple biochemical con-
nections leading potentially to EBL associated pathogen-
esis. The activation and involvement of hypoxia-inducible 
factor 1 in human T-cell leukemia virus type 1 (HTLV-
1) infected cell lines and primary adult T-cell leukemia 
(ATLL) cells was reported previously by [49]. It is of par-
ticular interest because HTLV-1 and BLV are characterized 
by similar genomic organization, similar strategies for gene 
expression, and similar pathologies. Figure  5 also shows 
direct and mutual protein interactions between HIF1A and 
AP1 (cJUN) and C/EBPα. It could be of interest that both 
CEBPA and c-JUN genes were downregulated in BLV 
infected cows in comparison to control group (−2.32-fold, 
p = 9.3E−06 and −1.85-fold, p = 5.53E−03, respectively), 
increasing the effect of hypoxic factors [25, 43, 53] in BLV-
associated disease progression.
In addition, the results of our transcription profiling 
indicted some aspects of innate immunity which could be 
impaired in BLV-infected animals. We noticed the differ-
ences in the mRNA expression levels of genes involved in 
the activation of the complement system, NK-cell cytotix-
icity and the TREM-1 signaling pathway. Namely, in the 
BLV-infected group we identified a decrease in the level of 
mRNAs for C1qA and C1qC constituents of the comple-
ment subcomponent C1q (−2.37-fold, p = 3.41E−03 and 
−1.9, p = 1.49E−03, respectively). This is of particular 
interest, because it has been reported previously that, the 
interaction and binding of human complement subcom-
ponent C1q with the gp-21 protein of HTLV-1 inhibits its 
infectivity [17]. Moreover, we also found in BLV-infected 
cattle an increased level of C1qBP (C1q-binding protein) 
mRNA (+1.99-fold, p = 3.03E−06), encoding a multifunc-
tional protein known to inhibit complement component C1 
activation by binding to globular heads of C1q molecules. 
C1qBP is also involved in cell proliferation, migration and 
apoptosis, and has been reported to be upregulated in many 
human cancers [30]. Finally, we observed a decreased 
expression of CFD (adipsin, complement factor D), CFB 
(complement factor B) and CFP (properdin, complement 
factor P) genes (−3.21-fold, p = 1.74E−10; −1.93-fold, 
p = 4.25E−03 and −1.66-fold, p = 3.8E−03, respectively), 
which were involved in the alternative pathway of the com-
plement system activation. The role of the alternative path-
way in the response against retroviral agents is unclear, but 
some clues indicate their contribution to leukemogenesis. 
The CFD gene encodes a serine protease, which cleaves the 
complement factor B, releasing a small fragment Ba and a 
larger fragment Bb. The Ba fragment of complement factor 
B inhibits human B-lymphocyte proliferation [3], while the 
Bb fragment acts as B-cell growth factor [36] and is further 
complexed with C3b and properdin to form C5 convertase, 
participating in the complement cascade. Both adipsin and 
properdin genes were reported among 50 genes useful for 
leukemia class prediction, allowing the distinguishing of 
acute lymphoblastic leukemia (ALL) from acute myeloid 
leukemia (AML) patients [15].
Gene ennrichment analysis (GeneGo by process net-
works) identified the Inflammation NK-cell cytotoxicity 
network (Table  8S) as the most significantly affected cat-
egory in our data set (FDR adjusted p value = 2.02-E03). 
This network comprises of 164 genes in total, and 18 
of them showed differential expression in our microar-
ray results. This is of interest as Natural Killer (NK) cells 
are lymphocytes of innate immunity that can participate 
in the lysis of some cancer cells and virus-infected cells 
with no previous activation. NK cells are also considered 
as important regulators of antiviral immune responses. In 
HTLV-1-infected individuals, the number of the NK cell 
was decreased and their activity was significantly impaired 
as compared to healthy controls [42]. Correspondingly, 
in BLV-infected cattle we found lower levels for mRNAs 
encoding NK-cell surface receptors, including KIR3DL3 
(−2, threefold, p = 1.0E−04), NKR2B4 (CD244) (−1.56-
fold, p = 1.48E−03), KLRC1 (NKG2A) (−1.77-fold, 
p = 4.77E−03) and NK-cell intracellular signaling pro-
teins, including tyrosine kinases PTK2B (FAK2) (−1.77-
fold, p = 1.55E−04),and its paralog SYK (+1.75-fold, 
p = 2.13E−05) and VAV3, encoding a guanine nucleotide 
exchange factor (−1.5-fold, p = 1.25E−03). In addition, a 
decreased level of TYROBP (DAP12) mRNA was observed 
(−2.54-fold, p = 1.83E−05). The TYROBP (TYRO Protein 
Tyrosine Kinase Binding Protein) gene encodes a trans-
membrane signaling protein, bearing an immunoreceptor 
tyrosinE−based activation motif (ITAM), and may be asso-
ciated with the crosslinking of natural killer-cell inhibitory 
receptor (KIR) family of membrane glycoproteins and sig-
nal transduction leading to NK-cells activation. Besides its 
involvement in NK-cell cytotoxicity, TYROBP also plays a 
crucial role in the TREM-1 signaling pathway, which has 
recently been suggested as a novel mechanism in antivi-
ral immunity [41]. Of interest is that TREM-1 signaling 
was also identified by enrichment analysis as the network 
significantly affected in our data set (Fig.  3b; Table  5S). 
Among genes with deregulated expression participating 
in the network we found TYROBP, SYK, protein kinase C 
inhibitor belonging to family 14-3-3 (YWHAG) (+1.57-
fold, p = 2.7E−04), inositol 1,4,5-triphosphate recep-
tor (ITPR1) (+1.57, p = 5.15E−03), caspase recruitment 
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domain containing adaptor protein member 9 (CARD9) 
(−1.57-fold, p = 5.24E−03), tissue inhibitor of metallopro-
teinases 1 (TIMP1) (−2.4-fold, p = 6.30E−05), interleu-
kin 8 (−1.58-fold p = 6.46E−03), and transcription factors 
c-JUN (−1.85-fold, p = 5.33E−03) and HMGB1 (+1.51, 
p = 0.16E−03). It seemed that BLV infection also affected 
the host’s innate immunity by the deregulation of the ubiq-
uitin pathways and the proteasome degradation processes. 
In the BLV-infected group we observed a decreased level 
of mRNAs for ITCH, encoding itchy E3 ubiquitin pro-
tein ligase (−2.3-fold, p = 1.72E−07). Of interest, it was 
reported that, ITCH overexpression strongly inhibited the 
release and infectivity of wild-type HTLV-1 [10].
The differences in leukocyte cell subpopulations found 
among the BLV-infected and non-infected cattle groups 
may be partially responsible for some of the identified gene 
expression changes. Nevertheless, the data showed in this 
report also reinforce the hypothesis that a host- or patho-
gen- or both-driven mechanism of innate immune gene 
repression might be of crucial importance for the outcome 
of BLV infection under natural conditions. It could be of 
interest that the cattle in the non-infected control group 
but exposed to BLV for at least 3 years in farm conditions 
were marked with the increased levels of mRNA transcripts 
associated with innate immunity. Disruption or deficiency 
of a suitable innate immune response may thus be crucial 
in BLV dissemination and progression to disease. Due to 
the paucity of information on innate antiviral response to 
BLV infection and disease progression, further studies are 
clearly needed.
Conclusion
Compared to earlier studies, we identified a significant 
number of new genes that have altered gene expres-
sion in BLV-infected blood cells. A higher number of 
down-regulated genes than up-regulated ones that have 
been noticed may reflect the viral latency state, typi-
cal for the majority of BLV-infected cells in  vivo and/
or it may characterize BLV-induced immunosupression. 
The latter could lead to the failure of efficient immune 
response and underlie the host evasion mechanism devel-
oped by BLV during evolution. Taking into account their 
function, the differentially expressed genes like: MSH2, 
APEX1, HIF1A, LMO2, CEBPA, and ITCH cast a new 
light on the mechanism of leukemogenesis associated 
with BLV and should be of particular interest in further 
studies. Furthermore, we have identified several new 
response pathways important for BLV-induced pathogen-
esis involving innate immunity including for the first time 
the complement system and TREM-1 signaling pathway, 
that are deregulated in BLV-infected cells. It provides a 
key for better understanding of the role of innate immu-
nity against retroviral agents and gives a promise for suc-
cessful intervening against them. However it should be 
emphasized that there are numerous regulatory processes 
that are targeted by BLV-infection and the complex net-
work of interrelated pathways is instead disturbed, caus-
ing the interruption of the control of B-cell proliferation 
and programmed cell death.
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